share_log

Avalo Therapeutics | SC 13G: Statement of acquisition of beneficial ownership by individuals-Cambyz Golestaneh(5.41%),Caissa Capital Management Ltd.(3.63%)

May 17, 2022 15:45
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more